Highlights Phio Pharmaceuticals Corp.

Equities

PHIO

US71880W4024

Delayed Nasdaq Other stock markets 10:17:52 09/05/2024 pm IST			5-day change	1st Jan Change
0.8393 ^USD	+4.91%		+8.20%	+10.43%

22/04	Phio Pharmaceuticals Corp. Presents New Data About Its Lead Clinical Product Candidate, PH-762	CI
16/04	Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Phio Pharmaceuticals Corp. Presents New Data About Its Lead Clinical Product Candidate, PH-762	22/04	CI
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology	16/04	CI
North American Morning Briefing : Stocks Seen -2-	02/04	DJ
Phio Pharmaceuticals Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	02/04	CI
Phio Pharmaceuticals Corp. Presents Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies	21/03	CI
Phio Pharmaceuticals Corp. Announces Addition of Clinical Trial Sites At Banner Md Anderson Cancer Center, the George Washington University, and Integrity Research	13/03	CI
Phio Pharmaceuticals Secures Patent for Compounds Treating Age Related Skin Disorders	06/03	MT
Phio Pharmaceuticals Corp. Announces Patent Granted by Uspto, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin Disorders	06/03	CI
Phio Pharmaceuticals Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Phio Pharmaceuticals Corp. Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas	09/11	CI
Phio Pharmaceuticals Corp. Announces the Presentation of New Preclinical Data At the 38Th Annual Meeting of the Society for Immunotherapy of Cancer	03/11	CI
Phio Pharmaceuticals Corp. Presents New Data for Targeting of BRD4 with its INTASYL Compound PH-894	11/23/11	CI
Phio Pharmaceuticals Corp. Announces Dosing of First Patient in Collaborative Clinical Trial with Agonox, Inc. and Providence Cancer Institute	21/23/21	CI
Phio Pharmaceuticals Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
Phio Pharmaceuticals Corp Presents Preclinical Study Showing INTASYL Treatment of NK Cells More than Doubles Ability to Kill Tumor Cells	18/23/18	CI
Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas	16/23/16	CI
Phio Pharmaceuticals Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12	CI
Phio Pharmaceuticals Corp. Announces Positive DMC Recommendation and Continued Enrollment of Advanced Melanoma Study Without Modification	10/23/10	CI
Reverse Split: 1 of 12	26/23/26	FA
Phio Pharmaceuticals Says US FDA Approves Clinical Trial With PH-762, AGX148 to Treat Solid Tumors	07/23/07	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Phio Pharmaceuticals Corp.

Equities

PHIO

US71880W4024

Highlights

Filters